The AbbVie team exploited co-crystal structures of BCL-2 and small-molecule inhibitors to guide their rational design of venetoclax (ABT-199), a first-in-class, highly specific inhibitor of BCL-2, and one of the first approved small-molecule tumor therapeutics that directly blocks a PPI25–28. This evidence concerns the gene BCL2 and neoplasm.